UCB partners with Harvard University to develop small molecules for the induction of autophagy to treat neurodegenerative diseases

UCB S.A.

Belgium / Mid-Cap Biopharma ($1-$50 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Harvard University

U.S. / Academic

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced